根据ESI于2024年1月发布的数据，我校高被引论文（Highly Cited Papers）404篇，热点论文（Hot Papers）13篇，见附件：2024年1月yl23455永利高被引论文及热点论文简表。详情如下。
从学科角度看，在404篇高被引论文中，临床医学最多（196篇），占比48.51%，分子生物学与遗传学35篇（8.66%）紧跟其后。
|
序号 |
高被引论文 Research Field |
202401 |
202311 |
||
|
论文数 |
占比 |
论文数 |
占比 |
||
|
1 |
CLINICAL MEDICINE |
196 |
48.51% |
180 |
48.65% |
|
2 |
MOLECULAR BIOLOGY & GENETICS |
35 |
8.66% |
34 |
9.19% |
|
3 |
BIOLOGY & BIOCHEMISTRY |
31 |
7.67% |
28 |
7.57% |
|
4 |
PHARMACOLOGY & TOXICOLOGY |
30 |
7.42% |
26 |
7.03% |
|
5 |
MATERIALS SCIENCE |
22 |
5.45% |
19 |
5.14% |
|
6 |
NEUROSCIENCE & BEHAVIOR |
19 |
4.70% |
17 |
4.60% |
|
7 |
ENGINEERING |
4 |
0.99% |
5 |
1.35% |
|
8 |
MICROBIOLOGY |
7 |
1.73% |
7 |
1.89% |
|
9 |
CHEMISTRY |
5 |
1.24% |
4 |
1.08% |
|
10 |
PHYSICS |
9 |
2.23% |
9 |
2.43% |
|
11 |
PSYCHIATRY/PSYCHOLOGY |
10 |
2.48% |
11 |
2.97% |
|
12 |
IMMUNOLOGY |
9 |
2.23% |
6 |
1.62% |
|
13 |
SOCIAL SCIENCES, GENERAL |
5 |
1.24% |
5 |
1.35% |
|
14 |
COMPUTER SCIENCE |
12 |
2.97% |
10 |
2.70% |
|
15 |
GEOSCIENCES |
1 |
0.25% |
1 |
0.27% |
|
16 |
AGRICULTURAL SCIENCES |
5 |
1.24% |
4 |
1.08% |
|
17 |
MULTIDISCIPLINARY |
1 |
0.25% |
1 |
0.27% |
|
18 |
ENVIRONMENT/ECOLOGY |
3 |
0.74% |
3 |
0.81% |
|
19 |
合计 |
404 |
100.00% |
370 |
100.00% |
|
序号 |
2024年1月我校13篇热点论文 标题 |
来源期刊 |
DOI |
Research Field |
Times Cited |
|
1 |
TRIAL OF ENDOVASCULAR THERAPY FOR ACUTE ISCHEMIC STROKE WITH LARGE INFARCT |
NEW ENGLAND JOURNAL OF MEDICINE 388 (14): 1272-1283 APR 6 2023 |
10.1056/NEJMoa2213379 |
CLINICAL MEDICINE |
79 |
|
2 |
ESTIMATED BURDEN OF STROKE IN CHINA IN 2020 |
JAMA NETWORK OPEN 6 (3): - MAR 2023 |
10.1001/jamanetworkopen.2023.1455 |
CLINICAL MEDICINE |
51 |
|
3 |
AENEAS: A RANDOMIZED PHASE III TRIAL OF AUMOLERTINIB VERSUS GEFITINIB AS FIRST-LINE THERAPY FOR LOCALLY ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER WITH EGFR EXON 19 DELETION OR L858R MUTATIONS |
JOURNAL OF CLINICAL ONCOLOGY 40 (27): 3162-+ SEP 20 2022 |
10.1200/JCO.21.02641 |
CLINICAL MEDICINE |
42 |
|
4 |
MACHINE LEARNING-BASED TUMOR-INFILTRATING IMMUNE CELL-ASSOCIATED LNCRNAS FOR PREDICTING PROGNOSIS AND IMMUNOTHERAPY RESPONSE IN PATIENTS WITH GLIOBLASTOMA |
BRIEFINGS IN BIOINFORMATICS 23 (6): - NOV 2022 |
10.1093/bib/bbac386 |
COMPUTER SCIENCE |
32 |
|
5 |
ASSOCIATION BETWEEN GUT MICROBIOTA AND PREECLAMPSIA-ECLAMPSIA: A TWO-SAMPLE MENDELIAN RANDOMIZATION STUDY |
BMC MEDICINE 20 (1): - NOV 15 2022 |
10.1186/s12916-022-02657-x |
CLINICAL MEDICINE |
32 |
|
6 |
OVERALL SURVIVAL WITH OSIMERTINIB IN RESECTED <I>EGFR</I>-MUTATED NSCLC |
NEW ENGLAND JOURNAL OF MEDICINE 389 (2): 137-147 JUL 13 2023 |
10.1056/NEJMoa2304594 |
CLINICAL MEDICINE |
20 |
|
7 |
BIODEGRADABLE AND CYTOCOMPATIBLE HYDROGEL COATING WITH ANTIBACTERIAL ACTIVITY FOR THE PREVENTION OF IMPLANT-ASSOCIATED INFECTION |
ACS APPLIED MATERIALS & INTERFACES : - FEB 28 2023 |
10.1021/acsami.2c20401 |
MATERIALS SCIENCE |
19 |
|
8 |
NEURAL STEM CELL-DERIVED EXOSOME AS A NANO-SIZED CARRIER FOR BDNF DELIVERY TO A RAT MODEL OF ISCHEMIC STROKE |
NEURAL REGENERATION RESEARCH 18 (2): 404-409 FEB 2023 |
10.4103/1673-5374.346466 |
NEUROSCIENCE & BEHAVIOR |
16 |
|
9 |
BIOMARKERS OF AGING |
SCIENCE CHINA-LIFE SCIENCES : - APR 11 2023 |
10.1007/s11427-023-2305-0 |
BIOLOGY & BIOCHEMISTRY |
14 |
|
10 |
VIRULENCE AND ADHESION OF THE TREPONEMA PALLIDUM <I>NICHOLS</I> STRAIN SIMULTANEOUSLY DECREASE IN A CONTINUOUS-INFECTION NEW ZEALAND WHITE RABBIT MODEL |
ACS INFECTIOUS DISEASES 9 (6): 1221-1231 MAY 16 2023 |
10.1021/acsinfecdis.2c00601 |
PHARMACOLOGY & TOXICOLOGY |
9 |
|
11 |
CAMRELIZUMAB PLUS RIVOCERANIB VERSUS SORAFENIB AS FIRST-LINE THERAPY FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA (CARES-310): A RANDOMISED, OPEN-LABEL, INTERNATIONAL PHASE 3 STUDY |
LANCET 402 (10408): 1133-1146 SEP 30 2023 |
10.1016/S0140-6736(23)00961-3 |
CLINICAL MEDICINE |
7 |
|
12 |
AGGREGATION-INDUCED EMISSION (AIE), LIFE AND HEALTH |
ACS NANO 17 (15): 14347-14405 JUL 24 2023 |
10.1021/acsnano.3c03925 |
MATERIALS SCIENCE |
6 |
|
13 |
BEFOTERTINIB (D-0316) VERSUS ICOTINIB AS FIRST-LINE THERAPY FOR PATIENTS WITH EGFR-MUTATED LOCALLY ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER: A MULTICENTRE, OPEN-LABEL, RANDOMISED PHASE 3 STUDY |
LANCET RESPIRATORY MEDICINE 11 (10): 905-915 OCT 2023 |
10.1016/S2213-2600(23)00183-2 |
CLINICAL MEDICINE |
4 |